Issue: October 2015
October 07, 2015
1 min read
Save

Trial Scorecard: TULIP

Issue: October 2015
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Researchers evaluated the CETP inhibitor TA-8995 for elevation in HDL and reduction in LDL alone and in combination with statin therapy.

Trial Scorecard: TULIP